CSL Limited (CSLLY) Stock Price & Analysis
CSL Limited (CSLLY) — price $33.01 (+0.33%), as of the Nov 19, 2026 trading session; market cap $63.4B.
Educational signal · not a buy or sell recommendation · How to read this
CSL Limited · CSLLY · Healthcare · Biotechnology
Research dated 2026-09-12: CSL is a scaled biopharmaceutical manufacturer whose sales come from plasma-derived and recombinant therapies, influenza-focused products, and related licensing income. Its defining financial question is whether a business that still produces substantial operating cash can restore the connection between revenue growth and net profit after a sharp earnings reversal.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $33.01 | |
| Change on the day | +0.33% | |
| 52-week range | $16.01–$36.88 | |
| Market capitalisation | $63.4B | — |
| Price / earnings (trailing) | 24.09 | |
| Shares traded on the day | 16.0K | |
| Beta (volatility vs the S&P 500) | 0.08 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for CSL (CSLLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is CSL (CSLLY), and what does it report?
Short answer · as of
CSL Behring supplies plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, respiratory deficiency, and neurological conditions, while Seqirus develops and supplies non-plasma biotherapeutics focused on influenza.
Research dated 2026-09-12.
Licensing and royalties supplement product revenue.
Reported revenue therefore combines treatment demand across serious chronic conditions, influenza-related product demand, and intellectual-property income. CSL is better understood as a global specialty-biologics producer than as a biotechnology company whose economics depend mainly on research milestones.
What do the latest results show for CSL (CSLLY)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $7.44B.
Research dated 2026-09-12.
Annual revenue continued to rise, but the company moved from substantial net profit to a substantial net loss. In the latest reported period, revenue declined from the preceding period, gross profit contracted, operating profit weakened, and the net result turned sharply negative.
The important change is the collapse in conversion from sales and operating profit into bottom-line earnings, rather than a disappearance of revenue. Operating cash flow remained positive and increased from the preceding period, so the earnings reversal did not produce a matching collapse in cash generated by the business.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $7.44B | -$2.99B | -$1.56 (diluted) |
| Q2 FY2026 | $8.30B | $402M | $0.05 (diluted) |
| Q4 FY2025 | $7.26B | $1.03B | $0.27 (diluted) |
| Q2 FY2025 | $8.21B | $2.01B | $0.26 (diluted) |
What are the financial strengths and risks for CSL (CSLLY)?
Short answer · as of
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
CSL continues to generate substantial operating cash after capital expenditure, and cash has remained broadly stable across the reported window despite fluctuations between periods. Short-term liquidity appears adequate, while the quality and distress screens remain favorable.
Debt nevertheless stands far above cash and investments, leaving the balance sheet in a net-debt position. The company-specific risk is prolonged divergence between positive operating profit and negative net income: continued charges below the operating line could weaken retained financial capacity even while the core businesses remain cash generative.
What should you watch next at CSL (CSLLY)?
Research dated 2026-09-12.
Watch whether net income reconnects with operating profit, whether gross profit stabilizes as revenue changes, and whether operating cash flow continues to cover capital expenditure. Cash should also be read against debt rather than in isolation, because recent cash stability does not remove the net-debt exposure.
Research spending deserves attention alongside the earnings recovery: CSL must support plasma, recombinant, and influenza programs while protecting cash generation. Published estimates imply restrained revenue progression and only modest later earnings improvement, making the direction of actual profit conversion more informative than revenue growth alone.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is CSL scored?
Research dated 2026-09-12.
CSL differs from a development-stage biotechnology company because it already manufactures and distributes commercial therapies at global scale, produces operating cash, and earns some licensing and royalty income. It also differs from a narrowly focused drugmaker because plasma-derived and recombinant therapies sit alongside an influenza-focused non-plasma operation.
That structure spreads demand across rare and serious conditions and influenza products, but it also makes consolidated revenue an imperfect guide to underlying economics. Product mix, gross-profit conversion, research spending, and the gap between operating and net income matter more than pipeline headlines alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $965.00 Nov 18, 2026 | $60.7B | — Model unavailable | |
| $44.52 Nov 18, 2026 | $73.3B | — Model unavailable | |
| $24.45 Nov 18, 2026 | $98.0B | — Model unavailable | |
| $521.80 Nov 19, 2026 | $32.2B | — Model unavailable | |
| $945.53 Nov 18, 2026 | $97.8B | — 5-pillar · not comparable | |
| $68.67 Nov 18, 2026 | $39.5B | — 5-pillar · not comparable | |
| $536.45 Nov 18, 2026 | $136B | — 5-pillar · not comparable | |
| $577.34 Nov 18, 2026 | $24.6B | — 5-pillar · not comparable | |
| $117.80 Nov 18, 2026 | $24.0B | — 5-pillar · not comparable | |
| $39.43 Nov 18, 2026 | $174B | — 5-pillar · not comparable | |
| $149.40 Nov 18, 2026 | $20.0B | — 5-pillar · not comparable | |
| $255.96 Nov 19, 2026 | $16.8B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CSLLY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CSLLY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CSL (CSLLY)?
What Investors Ask About CSL (CSLLY) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
How do CSL Behring and Seqirus differ?
CSL Behring concentrates on plasma-derived and recombinant therapies for serious medical conditions, while Seqirus focuses on non-plasma biotherapeutics related to influenza. Their revenue drivers therefore reflect different treatment categories within the same consolidated company.
What does CSL’s gap between operating profit and net loss mean?
The latest statements show that the business remained profitable at the operating line while the final result was deeply negative. Bottom-line earnings therefore deteriorated far more severely than revenue or operating activity.
Does CSL’s plasma therapy business still produce cash after the reported loss?
Consolidated operating cash flow remained substantial and exceeded capital expenditure despite the reported net loss. That cash performance separates the latest accounting loss from the cash generated by CSL’s operations, although the available figures do not isolate plasma therapies from Seqirus.
Why does CSL’s cash balance matter against its debt load?
Cash and investments provide liquidity, but they cover only a minority of total debt. CSL therefore depends more on continued operating cash generation than on its cash reserve alone when meeting financial obligations and funding investment.
What is the CSLLY stock price today?
The last price recorded for CSL Limited (CSLLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com